Logo image
Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity
Journal article   Open access   Peer reviewed

Practical Implementation of Genetics: New Concepts in Immunogenomics to Predict, Prevent, and Diagnose Drug Hypersensitivity

P. Deshpande, Y. Li, M. Thorne, A.M. Palubinsky, E.J. Phillips and A. Gibson
The Journal of Allergy and Clinical Immunology: In Practice
2022
pdf
drug hypersensitivity.pdf2.59 MBDownloadView
Author’s Version Open Access
url
Link to Published Version *Subscription may be requiredView

Abstract

Delayed drug hypersensitivities are CD8+ T-cell mediated reactions associated with up to 50% mortality. Human leukocyte antigen (HLA) alleles are known to predispose disease, specific to drug, reaction, and patient ethnicity, with pre-treatment screening recommended for a handful of the strongest associations to identify and prevent drug use in high-risk patients. However, an incomplete predictive value implicates other HLA-imposed risk factors, and low carriage of many identified HLA-risk alleles combined with the high cost of sequence-based typing has limited economic viability for similar recommendation of screening across drugs and healthcare systems. To mitigate, an expanding armoury of low-cost polymerase chain reaction-based screens is being developed, and HLA-imposed risk factors are being discovered. These include (i) polymorphic variants of metabolic and endoplasmic reticulum aminopeptidase enzymes, towards multi-allelic screening with increased predictivity, (ii) regulation by immune checkpoint inhibitors, enabling de-tolerised animal models of human disease, and (iii) immunodominant T-cell receptors (TCR) on clonally-expanded CD8+ T-cells. For the latter, HLA-risk restricted TCR provides immunogenomic strategies and samples from a single patient to identify (i) novel HLA-risk associations in underserved minority populations, (ii) tissue-relevant effector biomarkers towards earlier diagnosis and treatment, and (iii) HLA-TCR-presented immunogenic structures to aid future drug development.

Details

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Metrics

2 File views/ downloads
75 Record Views

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Collaboration types
Domestic collaboration
International collaboration
Citation topics
1 Clinical & Life Sciences
1.265 Dermatology - Skin Allergies
1.265.1140 Drug Hypersensitivity
Web Of Science research areas
Allergy
Immunology
ESI research areas
Clinical Medicine
Logo image